NIH Just Told Institutes They Can Fund You Below Your Own Notice of Award

Most continuing-resolution notices are administrative wallpaper. An agency confirms it is open, repeats that last year's rules still apply, and asks everyone to be patient. Researchers skim them and move on.

NOT-OD-26-131, released September 28, 2026, is not that notice. Buried in the standard language about Public Law 119-103 — the Continuing Appropriations and Extensions Act, 2027, signed September 2, 2026, which funds the government through December 11, 2026 at the FY 2026 enacted level — is a sentence with direct consequences for the cash in your account this quarter:

NIH Institutes and Centers may issue non-competing research grant awards at a level below that indicated on the most recent Notice of Award.

And its companion: "Upward adjustments to awarded levels will be considered after FY 2027 appropriations are enacted."

Read those two together and the operational reality becomes clear. The number on your current Notice of Award — the out-year commitment level your department built its staffing plan around — is not a floor. It is a projection that an Institute is now explicitly permitted to undercut, with restoration framed as something that will be considered, not something that will happen.

Why "Considered" Is the Load-Bearing Word

Grant administrators have lived through enough continuing resolutions to recognize the pattern: agencies issue reduced non-competing continuations, then true them up once full-year appropriations arrive. In many years, that is exactly what happens, and the reduction is a timing inconvenience rather than a loss.

But the notice does not promise a true-up. It commits NIH to considering one, and only after FY 2027 appropriations are enacted. Two things follow.

First, the timing is genuinely unknown. The CR runs to December 11, 2026. If Congress passes full-year appropriations in December, consideration of upward adjustments begins in the second quarter of FY 2027. If there is another CR — or a series of them, which has been the recent norm — that consideration slides indefinitely. A laboratory operating on a reduced Year 3 continuation from October 2026 could plausibly not see a restoration decision until well into calendar 2027, if it sees one at all.

Second, "considered" leaves the restoration contingent on the appropriated level. If FY 2027 lands below FY 2026, there is no pot from which to restore, and the reduced award simply becomes the award. Institutions that treat the reduction as a bridge loan against guaranteed future cash are making an assumption the notice does not support.

NIH's own instruction on this point is unambiguous and worth taking literally: recipients should monitor their expenditures carefully during this period. That is agency language for do not spend against the number you expected.

What This Does to a Real Budget

The damage from a reduced non-competing continuation is not distributed evenly across a budget. It concentrates in the places that are hardest to unwind.

Personnel is the first casualty, and the least reversible. A postdoctoral salary, a staff scientist, a research coordinator — these are committed effort with people attached. A ten percent reduction to a modular R01 continuation is roughly $25,000 on a $250,000 direct-cost year, which in most institutions is a substantial fraction of one full-time position with fringe. The reduction arrives as an administrative adjustment; absorbing it means a conversation with a human being whose visa status, lease, or family plans may depend on the answer. Institutions that wait for the restoration decision before having that conversation will have spent the money they were hoping to get back.

Carryover becomes strategically valuable in a way it usually is not. Unobligated balances are ordinarily something program officers scrutinize and institutions try to minimize. Under a reduced-continuation regime, an existing carryover balance is the single cleanest shock absorber available — it is cash already in hand, not contingent on an appropriations outcome. Projects sitting on carryover should be careful about spending it down in Q1 FY 2027 precisely because it is the only resource that does not depend on a congressional vote.

Subaward commitments are the sharpest edge. A prime recipient that has already executed subaward agreements at the full NoA level, and then receives a reduced continuation, is contractually exposed. Subrecipient institutions — often smaller, often with thinner reserves — have made their own hiring decisions against those documents. The prime's options are to reduce the subaward, absorb the shortfall centrally, or delay the subaward issuance until the reduced amount is known. All three are bad; the least bad is usually the third, and it requires knowing about the risk before the paperwork goes out. That calculation gets worse when combined with NIH's separate reversion to a $25,000 subaward cap on F&A recovery, which we examine in the companion analysis of NOT-OD-26-072.

Equipment and one-time purchases are the obvious place to hold. They are also where a reduction does the least long-term harm, which is exactly why a disciplined institutional response reallocates the pain there first rather than spreading it evenly.

Everything Else From FY 2026 Carries Forward Unchanged

The notice confirms that all FY 2026 legislative mandates and fiscal policies remain in effect, which includes the pieces most likely to trip up a budget being drafted right now.

The salary limitation continues at the Executive Level II rate. For FY 2026 that figure moved mid-year: $225,700 for awards issued October 1 through December 31, 2025, and $228,000 for awards issued January 1 through September 30, 2026, following NOT-OD-26-034 as corrected by NOT-OD-26-038 in February 2026. Budgets prepared for FY 2027 submissions under the CR should not assume a new cap figure until appropriations settle; there is no authority to budget above the continuing level.

NRSA stipend levels are likewise frozen at FY 2026 amounts. Training grant and fellowship budgets built on an anticipated annual stipend increase are budgeting against money that has not been appropriated.

The full slate of FY 2026 appropriations riders documented in NOT-OD-26-060 also persists: the Section 202 salary limitation, the Section 503 anti-lobbying restriction, the Sections 506 and 507 abortion provisions, the Section 210 prohibition on using funds to advocate or promote gun control, and the Section 525 restriction on purchasing sterile needles except in jurisdictions where a state or local health department has determined that an HIV or hepatitis outbreak is driven by injection drug use.

The anti-lobbying provision deserves particular attention this autumn, because NIH went out of its way to restate it. A September 24, 2026 Extramural Nexus post reminded recipients that NIH funds cannot be used for lobbying or advocacy. Publishing that reminder three weeks into a contested appropriations cycle, when grantees across the biomedical ecosystem are being urged by professional societies to contact Congress about research funding, is not a coincidence. Institutions should make sure the people drafting advocacy communications are not the people charging time to NIH awards.

The Section 157 Freeze Is a Second-Order Effect Worth Reading Correctly

The CR also prohibits implementation of revisions to the Uniform Guidance through December 11, 2026 — the Section 157 provision that halted the Uniform Grants Regulation proposed by OMB and 41 grantmaking agencies on May 29, 2026. We covered the mechanics of that freeze when HR 6500 was signed.

The temptation is to read this as unambiguously good news — the termination-for-convenience expansion, the political pre-issuance review, the elimination of fixed-amount awards all stay off the books for another ten weeks. That reading is correct as far as it goes. But there is a cost on the other side of the ledger that institutions building FY 2027 budgets should understand: the UGR's proposed 2 CFR 200.414(f) language and modified total direct cost definition were also the vehicle through which the more generous 15 percent de minimis rate and $50,000 subaward threshold would have become binding government-wide policy. Freezing the rule freezes both the threats and the relief.

The practical result is that the less favorable FY 2026 indirect-cost framework is now the planning baseline for every NIH budget being drafted between now and mid-December, with no prospect of regulatory change inside that window.

What to Actually Do in the Next Six Weeks

Reforecast every non-competing continuation at a reduced level and see what breaks. Pick a number — many institutions are modeling reductions in the range that recent CR periods have produced — and run it through the personnel line specifically. The output you want is not a revised budget; it is a list of named people whose effort is at risk and a decision about each one. Do that analysis before an Institute sends you a reduced NoA, not after.

Delay discretionary subaward issuance where you can, and warn subrecipients where you cannot. A subrecipient who learns in November that their Year 3 amount may shrink can adjust. One who learns in February, after hiring, cannot. The conversation is unpleasant and far cheaper than the alternative.

Protect carryover deliberately. If you have an unobligated balance, this is the quarter to document why you are holding it rather than racing to spend it. The institutional-risk argument is strong and program officers operating under the same CR will understand it.

Do not budget forward-year increases you cannot cite. Salary cap, stipend levels, and F&A treatment are all frozen at FY 2026 terms. A competing application or progress report that assumes otherwise invites a budget cut at the just-in-time stage.

Watch December 11, and watch what happens on December 12 more. Three outcomes are live: full-year appropriations that enable restoration consideration; another CR that extends this exact uncertainty and keeps the Section 157 freeze running; or a lapse. The second is the historical favorite, and planning for it means assuming your reduced continuation is your real budget through at least the second quarter of FY 2027.

The uncomfortable summary is that NIH has transferred a measure of appropriations risk from its own balance sheet onto individual projects, and done so in a notice most principal investigators will never read. The institutions that come through this cleanly will be the ones whose research administration offices translated one sentence about non-competing award levels into specific conversations about specific salaries, in October rather than in March.

If you are rebuilding a funding portfolio around a diversified base rather than a single federal continuation, Granted tracks the non-federal and state programs that do not share NIH's appropriations calendar — which is a different kind of hedge than carryover, and a more durable one.